The FDA has approved Leqembi Iqlik (lecanemab-irmb) subcutaneous weekly starting dose, enabling fully at-home treatment ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena ...
One of South Carolina’s top providers of MSC injections opens a new clinic to offer services to more patients in the area. MOUNT PLEASANT, SC, UNITED STATES, June ...
Credit: AstraZeneca. The new weekly 120 mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.
Subcutaneous anifrolumab 120mg weekly demonstrated a statistically significant and clinically meaningful reduction in SLE disease activity (58.5% BICLA response vs 43.2% for placebo) with a safety ...
The Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Leqembi ® Iqlik ™, a once weekly lecanemab-irmb subcutaneous (SC) injection, for maintenance dosing to ...
COLUMBIA, S.C. (WCSC/AP) - A South Carolina man was put to death by lethal injection Friday evening in the state’s sixth execution in nine months. Stephen Stanko, 57, was sentenced for two separate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results